Literature DB >> 19410391

The effects of oestrogen on urogenital health.

Michèle Lachowsky1, Rossella E Nappi.   

Abstract

The decline in sex hormone levels that accompanies the menopause has substantial effects on the tissues of the urogenital system, leading to atrophic changes. These changes can have negative effects on sexual and urinary function, leading to dyspareunia and incontinence. Treatment of urogenital atrophy with systemic or local oestrogens can improve the adverse effects of loss of oestrogen on both sexual and urinary functions. In some cases, treatment with oestrogen alone may not be sufficient to address sexual problems in menopausal women and androgen addition is required. Because of the complexity of sexual problems in menopausal women, assessment and therapy should address both the physical and other factors that play a role in the condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19410391     DOI: 10.1016/j.maturitas.2009.03.012

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  3 in total

1.  Dyspareunia in HIV-positive and HIV-negative middle-aged women: a cross-sectional study.

Authors:  Ana L R Valadares; Aarão M Pinto-Neto; Debora de C Gomes; Walquíria C D'Avanzo; Alexandre S Moura; Lúcia Costa-Paiva; Maria Helena de Sousa
Journal:  BMJ Open       Date:  2014-11-24       Impact factor: 2.692

2.  A comparative study of vaginal estrogen cream and sustained-release estradiol vaginal tablet (Vagifem) in the treatment of atrophic vaginitis in Isfahan, Iran in 2010-2012.

Authors:  Pardis Hosseinzadeh; Atallah Ghahiri; Freshteh Daneshmand; Mojdeh Ghasemi
Journal:  J Res Med Sci       Date:  2015-12       Impact factor: 1.852

3.  Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.

Authors:  R E Nappi; S Palacios; N Panay; M Particco; M L Krychman
Journal:  Climacteric       Date:  2015-11-19       Impact factor: 3.005

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.